Swedish Orphan Biovitrum AB

A US Centers for Disease Control and Prevention panel’s divided endorsement of Merck & Co .’s Enflonsia (clesrovimab-cfor) for prevention of respiratory syncytial virus in infants suggests that p

The US Food and Drug Administration approved Merck & Co.’s Enflonsia (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infa

England’s health technology assessment (HTA) institute, NICE, has recommended in favor of making Pfizer’s Hympavzi (marstacimab) available on the National Health Service for preventing severe hemophil

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Eyenovia, Betaliq Will Have Combined C